GEJ Adenocarcinoma
9 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers (NCT04430738) | Seagen, a wholly owned subsidiary of Pfizer | 2020-09-15 |
Track GEJ Adenocarcinoma automatically
Every clearance here is in the API, with alerts when new ones post.